Last reviewed 2026-04-20 · How we verify

Isauvuconazole group (isauvuconazole-group)

Pfizer · FDA-approved active Quality 40/100

Isauvuconazole group (generic name: isauvuconazole-group) is a Echinocandin drug developed by Pfizer. It is currently FDA-approved (first approved Not ) for Aspergillosis, Mucormycosis, Sporotrichosis.

Isauvuconazole is an investigational antifungal agent being developed by Pfizer Inc. It belongs to the echinocandin class of drugs and is designed to inhibit the synthesis of fungal cell walls. Despite its promising preclinical and clinical data, it has not yet received FDA approval. The drug is currently in late-stage development for the treatment of invasive fungal infections, particularly in immunocompromised patients. Safety profiles from clinical trials suggest that it is generally well-tolerated, but specific side effects and their frequencies are still under evaluation.

At a glance

Generic name	isauvuconazole-group
Sponsor	Pfizer
Drug class	Echinocandin
Target	β-(1,3)-D-glucan synthase
Therapeutic area	Other
Phase	FDA-approved
First approval	Not yet launched

Approved indications

Aspergillosis
Mucormycosis
Sporotrichosis
Candidemia and Invasive Candidiasis
Invasive Aspergillosis
Invasive Mucormycosis
Invasive Candidiasis
Sporotrichosis
Invasive Aspergillosis
Invasive Mucormycosis
Candidemia
Invasive Candidiasis
Sporotrichosis
Invasive Aspergillosis
Invasive Mucormycosis
Candidemia
Invasive Candidiasis
Sporotrichosis
Invasive Aspergillosis
Invasive Mucormycosis

Pipeline indications

Common side effects

No common side effects on file.

Drug interactions

Rifampicin
Carbamazepine
Phenytoin
Ethinyl estradiol
Atorvastatin
Midazolam
Omeprazole
Cyclosporine
Tacrolimus
Warfarin
Digoxin
Theophylline

Key clinical trials

Post Marketing Surveillance (PMS) Study of Cresemba in Korea.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Isauvuconazole group CI brief — competitive landscape report
Isauvuconazole group updates RSS · CI watch RSS
Pfizer portfolio CI

Frequently asked questions about Isauvuconazole group

What is Isauvuconazole group?

Isauvuconazole group (isauvuconazole-group) is a Echinocandin drug developed by Pfizer, indicated for Aspergillosis, Mucormycosis, Sporotrichosis.

What is Isauvuconazole group used for?

Isauvuconazole group is indicated for Aspergillosis, Mucormycosis, Sporotrichosis, Candidemia and Invasive Candidiasis, Invasive Aspergillosis.

Who makes Isauvuconazole group?

Isauvuconazole group is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What is the generic name of Isauvuconazole group?

isauvuconazole-group is the generic (nonproprietary) name of Isauvuconazole group.

What drug class is Isauvuconazole group in?

Isauvuconazole group belongs to the Echinocandin class. See all Echinocandin drugs at /class/echinocandin.

When was Isauvuconazole group approved?

Isauvuconazole group was first approved on Not yet launched.

What development phase is Isauvuconazole group in?

Isauvuconazole group is FDA-approved (marketed).

What does Isauvuconazole group target?

Isauvuconazole group targets β-(1,3)-D-glucan synthase and is a Echinocandin.

Drug class: All Echinocandin drugs
Target: All drugs targeting β-(1,3)-D-glucan synthase
Manufacturer: Pfizer — full pipeline
Therapeutic area: All drugs in Other
Indication: Drugs for Aspergillosis
Indication: Drugs for Mucormycosis
Indication: Drugs for Sporotrichosis

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing